1
|
Panova VA, Filimonov SI, Chirkova ZV, Kabanova MV, Shetnev AA, Korsakov MK, Petzer A, Petzer JP, Suponitsky KY. Investigation of pyrazolo[1,5-a]quinoxalin-4-ones as novel monoamine oxidase inhibitors. Bioorg Chem 2020; 108:104563. [PMID: 33376014 DOI: 10.1016/j.bioorg.2020.104563] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Revised: 12/07/2020] [Accepted: 12/13/2020] [Indexed: 11/24/2022]
Abstract
The monoamine oxidase (MAO) enzymes are key metabolic enzymes of neurotransmitter and other bioactive amines, and represent important drug targets for the treatment of neuropsychiatric and neurodegenerative disorders. Inhibitors of MAO are established medications for the treatment of depression and Parkinson's disease, and may have future roles in other disease states such as the therapy of prostate cancer, cardiovascular disease and inflammatory diseases. Based on these considerations, the present study synthesizes a series of 22 pyrazolo[1,5-a]quinoxalin-4-one derivatives and evaluated them as potential inhibitors of human MAO-A and MAO-B. The results show that 8 derivatives inhibit MAO-A, and 3 derivatives inhibit MAO-B with IC50 values in the submicromolar range (<1 µM). The most potent MAO-A inhibitor, N-[5-(acetyloxy)-2-(4-chlorophenyl)-4-oxo-4,5-dihydropyrazolo[1,5-a]quinoxalin-7-yl]acetamide (7c), exhibit an IC50 value of 0.028 µM and displays 50-fold selectivity for MAO-A over MAO-B. The most potent MAO-B inhibitor, 2-(4-methylphenyl)-4-oxo-4,5-dihydropyrazolo[1,5-a]quinoxaline-7-carbonitrile (4f), exhibit an IC50 value of 0.617 µM and displays 8-fold selectivity for MAO-B. This is the first report of MAO inhibition by pyrazolo[1,5-a]quinoxalin-4-one derivatives, and this study concludes that these compounds are suitable leads for the future development of MAO inhibitors, particularly of the MAO-A isoform.
Collapse
Affiliation(s)
- Valeria A Panova
- Pharmaceutical Technology Transfer Center, Yaroslavl State Pedagogical University named after K.D. Ushinsky, 108 Respublikanskaya St., Yaroslavl, Russian Federation.
| | - Sergey I Filimonov
- Yaroslavl State Technical University, 88 Moskovskii av., Yaroslavl, Russian Federation.
| | - Zhanna V Chirkova
- Yaroslavl State Technical University, 88 Moskovskii av., Yaroslavl, Russian Federation.
| | - Mariya V Kabanova
- Yaroslavl State Technical University, 88 Moskovskii av., Yaroslavl, Russian Federation.
| | - Anton A Shetnev
- Pharmaceutical Technology Transfer Center, Yaroslavl State Pedagogical University named after K.D. Ushinsky, 108 Respublikanskaya St., Yaroslavl, Russian Federation.
| | - Mikhail K Korsakov
- Pharmaceutical Technology Transfer Center, Yaroslavl State Pedagogical University named after K.D. Ushinsky, 108 Respublikanskaya St., Yaroslavl, Russian Federation.
| | - Anél Petzer
- Pharmaceutical Chemistry and Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom 2520, South Africa.
| | - Jacobus P Petzer
- Pharmaceutical Chemistry and Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom 2520, South Africa.
| | - Kyrill Yu Suponitsky
- A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Vavilov St. 28, Moscow 119991, Russian Federation; G.V. Plekhanov Russian University of Economics, Stremyanny per. 36, Moscow 117997, Russian Federation.
| |
Collapse
|
2
|
|